Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria
Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of 18fluorodeoxyglucose–positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criter...
Saved in:
Published in | Annals of oncology Vol. 20; no. 3; pp. 503 - 507 |
---|---|
Main Authors | , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford
Oxford University Press
01.03.2009
Oxford Publishing Limited (England) |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of 18fluorodeoxyglucose–positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criteria (IWC) remains to be established. Patients and methods: In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles. Results: Median age was 53 years (19–79), 68% male. The International Prognostic Index was low = 22%, low-intermediate = 19%, intermediate-high = 33% and high risk = 26%. Treatment consisted of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) (30%) or dose-intensified CHOP (70%), with rituximab (49%) or without (51%). Ninety-nine patients were evaluated by PET and IWC at four cycles: 77 (78%) had a negative PET, while 22 (22%) remained positive. The 5-year event-free survival (EFS) was 36% for patients with a positive PET versus 80% with a negative examination, whatever the response [complete response (CR) versus partial response (PR)] according to IWC (P < 0.0001). Positive PET patients had a 5-year EFS of 58% if in CR/CR unconfirmed by IWC and 0% if not (P < 0.0001). The same observations could be made in patients treated with and without rituximab. Conclusion: The integration of PET in treatment evaluation offers a powerful tool to predict outcome. |
---|---|
AbstractList | Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of [sup]18fluorodeoxyglucose-positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criteria (IWC) remains to be established. Patients and methods: In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles. Results: Median age was 53 years (19-79), 68% male. The International Prognostic Index was low = 22%, low-intermediate = 19%, intermediate-high = 33% and high risk = 26%. Treatment consisted of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) (30%) or dose-intensified CHOP (70%), with rituximab (49%) or without (51%). Ninety-nine patients were evaluated by PET and IWC at four cycles: 77 (78%) had a negative PET, while 22 (22%) remained positive. The 5-year event-free survival (EFS) was 36% for patients with a positive PET versus 80% with a negative examination, whatever the response [complete response (CR) versus partial response (PR)] according to IWC (P < 0.0001). Positive PET patients had a 5-year EFS of 58% if in CR/CR unconfirmed by IWC and 0% if not (P < 0.0001). The same observations could be made in patients treated with and without rituximab. Conclusion: The integration of PET in treatment evaluation offers a powerful tool to predict outcome. Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of (18)fluorodeoxyglucose-positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criteria (IWC) remains to be established. In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles. Median age was 53 years (19-79), 68% male. The International Prognostic Index was low=22%, low-intermediate=19%, intermediate-high=33% and high risk=26%. Treatment consisted of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) (30%) or dose-intensified CHOP (70%), with rituximab (49%) or without (51%). Ninety-nine patients were evaluated by PET and IWC at four cycles: 77 (78%) had a negative PET, while 22 (22%) remained positive. The 5-year event-free survival (EFS) was 36% for patients with a positive PET versus 80% with a negative examination, whatever the response [complete response (CR) versus partial response (PR)] according to IWC (P<0.0001). Positive PET patients had a 5-year EFS of 58% if in CR/CR unconfirmed by IWC and 0% if not (P<0.0001). The same observations could be made in patients treated with and without rituximab. The integration of PET in treatment evaluation offers a powerful tool to predict outcome. Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of 18fluorodeoxyglucose–positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criteria (IWC) remains to be established. Patients and methods: In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles. Results: Median age was 53 years (19–79), 68% male. The International Prognostic Index was low = 22%, low-intermediate = 19%, intermediate-high = 33% and high risk = 26%. Treatment consisted of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) (30%) or dose-intensified CHOP (70%), with rituximab (49%) or without (51%). Ninety-nine patients were evaluated by PET and IWC at four cycles: 77 (78%) had a negative PET, while 22 (22%) remained positive. The 5-year event-free survival (EFS) was 36% for patients with a positive PET versus 80% with a negative examination, whatever the response [complete response (CR) versus partial response (PR)] according to IWC (P < 0.0001). Positive PET patients had a 5-year EFS of 58% if in CR/CR unconfirmed by IWC and 0% if not (P < 0.0001). The same observations could be made in patients treated with and without rituximab. Conclusion: The integration of PET in treatment evaluation offers a powerful tool to predict outcome. Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of 18fluorodeoxyglucose-positron emission tomography (PET) in posttreatment evaluation. The value of PET after four cycles compared with the International Workshop Criteria (IWC) remains to be established. Patients and methods: In all, 103 patients with untreated diffuse large B-cell lymphoma were prospectively enrolled to evaluate the prognostic impact of PET after two and four cycles. Results: Median age was 53 years (19-79), 68% male. The International Prognostic Index was low = 22%, low-intermediate = 19%, intermediate-high = 33% and high risk = 26%. Treatment consisted of cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) (30%) or dose-intensified CHOP (70%), with rituximab (49%) or without (51%). Ninety-nine patients were evaluated by PET and IWC at four cycles: 77 (78%) had a negative PET, while 22 (22%) remained positive. The 5-year event-free survival (EFS) was 36% for patients with a positive PET versus 80% with a negative examination, whatever the response [complete response (CR) versus partial response (PR)] according to IWC (P < 0.0001). Positive PET patients had a 5-year EFS of 58% if in CR/CR unconfirmed by IWC and 0% if not (P < 0.0001). The same observations could be made in patients treated with and without rituximab. Conclusion: The integration of PET in treatment evaluation offers a powerful tool to predict outcome. |
Author | Rahmouni, A. Dupuis, J. Gisselbrecht, C. Itti, E. Belhadj, K. El Gnaoui, T. Kuhnowski, F. Lin, C. Gaillard, I. Haioun, C. Hemery, F. Copie-Bergman, C. Meignan, M. |
Author_xml | – sequence: 1 givenname: J. surname: Dupuis fullname: Dupuis, J. organization: Department of Clinical Hematology – sequence: 2 givenname: E. surname: Itti fullname: Itti, E. organization: Department of Nuclear Medicine – sequence: 3 givenname: A. surname: Rahmouni fullname: Rahmouni, A. organization: Department of Radiology – sequence: 4 givenname: F. surname: Hemery fullname: Hemery, F. organization: Department of Biostatistics, Université Paris 12, Créteil; Assistance Publique—Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Créteil – sequence: 5 givenname: C. surname: Gisselbrecht fullname: Gisselbrecht, C. organization: Department of Hematology-Oncology, AP-HP, Hôpital Saint Louis, Paris, France – sequence: 6 givenname: C. surname: Lin fullname: Lin, C. organization: Department of Nuclear Medicine – sequence: 7 givenname: C. surname: Copie-Bergman fullname: Copie-Bergman, C. organization: Inserm U841 (Equipe 9) and Pathology, Université Paris 12, Créteil; Assistance Publique—Hôpitaux de Paris (AP-HP), Hôpital Henri Mondor, Créteil – sequence: 8 givenname: K. surname: Belhadj fullname: Belhadj, K. organization: Department of Clinical Hematology – sequence: 9 givenname: T. surname: El Gnaoui fullname: El Gnaoui, T. organization: Department of Clinical Hematology – sequence: 10 givenname: I. surname: Gaillard fullname: Gaillard, I. organization: Department of Clinical Hematology – sequence: 11 givenname: F. surname: Kuhnowski fullname: Kuhnowski, F. organization: Department of Clinical Hematology – sequence: 12 givenname: M. surname: Meignan fullname: Meignan, M. organization: Department of Nuclear Medicine – sequence: 13 givenname: C. surname: Haioun fullname: Haioun, C. email: corinne.haioun@hmn.aphp.fr, Correspondence to: Dr C. Haioun, Service d'Hématologie Clinique, Hôpital H. Mondor, 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil, France. Tel: +33-1-49-81-20-51; Fax: +33-1-49-81-20-67; corinne.haioun@hmn.aphp.fr organization: Department of Clinical Hematology |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=21231111$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/19074215$$D View this record in MEDLINE/PubMed |
BookMark | eNqFkU9v1DAQxS1URNuFI1dkISFxCbVjx4m5lRWwFSsV8UdUXCI3mey6m9jBdmD3c_MFmGVX5chcxrJ_783I75ycOO-AkKecveJMiwvj8KK5GFqnSv6AnPFC6axikp-QM6ZzkZWFkKfkPMY7xpjSuX5ETrlmpcx5cUZ-f4I4eheBmhghxgFcoqZLEKhx1Lp2apL9CXS-uP5Iffjbs95ugAZYWaTpL5vW-5d991OiwaZpawdzi2rKmaCjSRZd44FsbddNOK43YQX0TdZA39N-N4xrP5jXqEmwCqhwK8qrrp988C347W7VT41H3eijTcE7CoON0eIh-cGjZFzv8EjTGugVmgSHJt6Znn7zYRPXfqRzXA2CNY_Jw870EZ4c-4x8fff2y3yRLa_fX80vl1kjmOCZMaXkRrRQtpXmwHnRMqaV4Vo2qsobo3Sryk6qincSK9dK5WXDpS6kklUlZuT5wXcM_scEMdV3fsK9-lhzZAWTOGdGsgPUBB9jgK4eA_5e2NWc1fuE60PC9SFh5J8dTafbAdp_9DFSBF4cARMb03fBuMbGey7nueBYyL08cH4a_zvzuKONCbb3sAmbWpWiLOrFzfda5Tfzz8tC1h_EHwwX1CA |
CitedBy_id | crossref_primary_10_1007_s00330_019_06552_7 crossref_primary_10_1182_blood_2019003277 crossref_primary_10_3324_haematol_2019_243386 crossref_primary_10_1016_j_mayocp_2012_03_006 crossref_primary_10_1631_jzus_B2200644 crossref_primary_10_2217_fon_13_55 crossref_primary_10_1007_s11899_012_0129_y crossref_primary_10_1016_j_mayocp_2011_11_007 crossref_primary_10_1259_bjr_20210576 crossref_primary_10_3109_10428194_2015_1007506 crossref_primary_10_1111_ejh_12416 crossref_primary_10_1053_j_seminhematol_2015_01_001 crossref_primary_10_1007_s12149_011_0549_0 crossref_primary_10_1007_s00259_013_2686_2 crossref_primary_10_1093_qjmed_hcv039 crossref_primary_10_5045_br_2014_49_2_107 crossref_primary_10_18632_oncotarget_13065 crossref_primary_10_1002_ajh_22270 crossref_primary_10_1111_bjh_13036 crossref_primary_10_1111_j_1365_2141_2010_08162_x crossref_primary_10_1200_JCO_2013_53_5229 crossref_primary_10_1007_s12185_013_1444_3 crossref_primary_10_1080_10428194_2016_1233543 crossref_primary_10_1080_10428194_2019_1599115 crossref_primary_10_1002_cam4_2798 crossref_primary_10_3109_10428194_2013_784967 crossref_primary_10_1007_s11864_014_0278_4 crossref_primary_10_1093_annonc_mdu109 crossref_primary_10_3109_10428194_2011_614704 crossref_primary_10_1182_blood_2020005649 crossref_primary_10_1200_JCO_2015_62_0229 crossref_primary_10_1200_JCO_2011_38_2648 crossref_primary_10_1007_s12254_015_0215_7 crossref_primary_10_3109_10428190903308056 crossref_primary_10_1182_blood_2009_08_234351 crossref_primary_10_1002_ajh_24128 crossref_primary_10_1159_000485548 crossref_primary_10_1002_cncr_25579 crossref_primary_10_1016_j_blre_2016_06_003 crossref_primary_10_1200_JCO_2010_32_5225 crossref_primary_10_1016_j_bbmt_2010_11_017 crossref_primary_10_1016_j_ijrobp_2012_01_060 crossref_primary_10_1182_blood_2010_12_327767 crossref_primary_10_1186_s12885_022_09486_4 crossref_primary_10_1016_j_mednuc_2018_12_016 crossref_primary_10_1002_2056_4538_12370 crossref_primary_10_1097_RLU_0000000000003756 crossref_primary_10_1016_j_cpet_2011_12_004 crossref_primary_10_3816_CLML_2010_n_086 crossref_primary_10_1007_s00259_021_05353_9 crossref_primary_10_1182_blood_2016_05_672196 crossref_primary_10_1007_s12032_014_0880_0 crossref_primary_10_1148_radiol_2015150689 crossref_primary_10_1586_17474086_2016_1146584 |
Cites_doi | 10.2967/jnumed.107.046292 10.2967/jnumed.107.042093 10.1200/JCO.2005.01.891 10.1200/JCO.2005.09.131 10.1080/10428190701474365 10.1056/NEJMoa042040 10.1200/JCO.2006.09.2403 10.1093/annonc/mdf256 10.2967/jnumed.107.039867 10.1182/blood-2005-01-0272 10.3324/haematol.10895 10.1080/01621459.1958.10501452 10.1200/JCO.1999.17.4.1244 10.1002/cncr.21253 10.1200/JCO.2007.11.9248 10.1093/annonc/mdi272 10.1200/JCO.2006.08.2305 |
ContentType | Journal Article |
Copyright | The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org 2009 2009 INIST-CNRS The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org |
Copyright_xml | – notice: The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org 2009 – notice: 2009 INIST-CNRS – notice: The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org |
DBID | BSCLL IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TM 7TO H94 K9. |
DOI | 10.1093/annonc/mdn671 |
DatabaseName | Istex Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Nucleic Acids Abstracts Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Oncogenes and Growth Factors Abstracts Nucleic Acids Abstracts |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1569-8041 |
EndPage | 507 |
ExternalDocumentID | 1656082471 10_1093_annonc_mdn671 19074215 21231111 10.1093/annonc/mdn671 ark_67375_HXZ_62XCSL54_K |
Genre | Journal Article |
GroupedDBID | --- -E4 .2P .86 .I3 .XZ .ZR 08P 0R~ 1TH 23M 2WC 4.4 482 48X 53G 5GY 5VS 5WA 6.Y 6J9 70D AABJS AABMN AAEDW AAESY AAIAV AAIYJ AAJKP AAJQQ AAKAS AAKUH AAMVS AAOGV AAPNW AAUQX AAXUO ABEUO ABIXL ABJNI ABKDP ABLJU ABNKS ABOCM ABQLI ABQTQ ABVKL ABZBJ ACGFO ACGFS ACIMA ACPRK ACUFI ACUTO ADBBV ADEIU ADEYI ADHKW ADHZD ADJQC ADOCK ADORX ADQLU ADRIX ADRTK ADYVW ADZCM ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AEWNT AFIYH AFOFC AFXEN AGINJ AGKEF AGSYK AHMBA AHXPO AIAGR AIJHB AIKOY AITUG ALMA_UNASSIGNED_HOLDINGS ALUQC AMRAJ APIBT APWMN ASMCH ASPBG AVWKF AWCFO AXUDD AZFZN AZQFJ BAWUL BAYMD BGYMP BHONS BSCLL BTRTY BVRKM C1A CAG CASEJ CDBKE CKLRP COF CS3 CZ4 DAKXR DIK DILTD DPORF DPPUQ D~K E3Z EBS EE~ EJD EX3 F9B FDB FEDTE GJXCC GX1 H5~ HAR HVGLF HW0 HZ~ I09 IH2 IOX J21 KAQDR KOM KOP KQ8 KSI KSN M-Z M41 M49 MHKGH N9A NCXOZ NGC NOYVH NU- NVLIB O9- OAWHX ODMLO OJQWA OK1 OVD P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX RW1 RXO TCURE TEORI TJX TR2 W8F WOQ WOW X7H YAYTL YFH YKOAZ ZKX ~91 0SF 0U7 AALRI ABSAR ABSMQ ACMRT ACPQN ADVLN AEKPW AFETI AFSHK AGKRT AKRWK AQKUS ATTQO BGNMA BZKNY DL5 H13 IHE KC5 KDC LAK M4Y MBLQV NTWIH NU0 QBD RNI ROZ RPX RZC RZE RZF RZO SDH TMA U2A ZXP ABMYL IQODW AEHUL AFJKZ CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TM 7TO H94 K9. |
ID | FETCH-LOGICAL-c3031-aa741a3de7d891e115d0096a194c682ca69d67f4681f4444296627c1495464883 |
ISSN | 0923-7534 |
IngestDate | Fri Sep 13 04:33:51 EDT 2024 Thu Sep 26 16:21:47 EDT 2024 Sat Sep 28 08:31:03 EDT 2024 Thu Mar 14 17:31:29 EDT 2024 Wed Sep 11 04:50:58 EDT 2024 Sun Mar 31 11:38:15 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Keywords | fluorodeoxyglucose PET scan response Criteria diffuse large B-cell lymphoma rituximab Radionuclide study Antineoplastic agent Human Evaluation Drug combination Rituximab Patient B cell neoplasm Malignant hemopathy Monoclonal antibody CHOP protocol Treatment 18fluorodeoxyglucose PET scan Lymphoproliferative syndrome Immunotherapy Diffuse large B cell lymphoma Workshop Positron emission tomography Cancer International Emission tomography |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c3031-aa741a3de7d891e115d0096a194c682ca69d67f4681f4444296627c1495464883 |
Notes | istex:59EE3CBC0391E46AA2D5C424F3F52F10E56EF746 ark:/67375/HXZ-62XCSL54-K |
OpenAccessLink | http://www.annalsofoncology.org/article/S0923753419414014/pdf |
PMID | 19074215 |
PQID | 196630430 |
PQPubID | 29775 |
PageCount | 5 |
ParticipantIDs | proquest_journals_196630430 crossref_primary_10_1093_annonc_mdn671 pubmed_primary_19074215 pascalfrancis_primary_21231111 oup_primary_10_1093_annonc_mdn671 istex_primary_ark_67375_HXZ_62XCSL54_K |
PublicationCentury | 2000 |
PublicationDate | 2009-Mar |
PublicationDateYYYYMMDD | 2009-03-01 |
PublicationDate_xml | – month: 03 year: 2009 text: 2009-Mar |
PublicationDecade | 2000 |
PublicationPlace | Oxford |
PublicationPlace_xml | – name: Oxford – name: England |
PublicationTitle | Annals of oncology |
PublicationTitleAlternate | Ann Oncol |
PublicationYear | 2009 |
Publisher | Oxford University Press Oxford Publishing Limited (England) |
Publisher_xml | – name: Oxford University Press – name: Oxford Publishing Limited (England) |
References | Cheson (10.1093/annonc/mdn671_bb0030) 1999; 17 Zijlstra (10.1093/annonc/mdn671_bb0015) 2006; 91 Terasawa (10.1093/annonc/mdn671_bb0020) 2008; 49 Isasi (10.1093/annonc/mdn671_bb0010) 2005; 104 Brepoels (10.1093/annonc/mdn671_bb0040) 2007; 48 Jaffe (10.1093/annonc/mdn671_bb0095) 2001 Dupuis (10.1093/annonc/mdn671_bb0100) 2007; 92 Feugier (10.1093/annonc/mdn671_bb0080) 2005; 23 Kaplan (10.1093/annonc/mdn671_bb0090) 1958; 53 Juweid (10.1093/annonc/mdn671_bb0050) 2007; 25 Mikhaeel (10.1093/annonc/mdn671_bb0065) 2005; 16 Haioun (10.1093/annonc/mdn671_bb0060) 2005; 106 Reyes (10.1093/annonc/mdn671_bb0075) 2005; 352 Haioun (10.1093/annonc/mdn671_bb0085) 2005 Juweid (10.1093/annonc/mdn671_bb0025) 2008; 49 Spaepen (10.1093/annonc/mdn671_bb0055) 2002; 13 Juweid (10.1093/annonc/mdn671_bb0035) 2005; 23 Lin (10.1093/annonc/mdn671_bb0070) 2007; 48 Cheson (10.1093/annonc/mdn671_bb0045) 2007; 25 Krishnan (10.1093/annonc/mdn671_bb0105) 2008; 26 |
References_xml | – volume: 49 start-page: 9 year: 2008 ident: 10.1093/annonc/mdn671_bb0025 article-title: 18F-FDG PET as a routine test for posttherapy assessment of Hodgkin's disease and aggressive non-Hodgkin's lymphoma: where is the evidence? publication-title: J Nucl Med doi: 10.2967/jnumed.107.046292 contributor: fullname: Juweid – volume: 48 start-page: 1626 year: 2007 ident: 10.1093/annonc/mdn671_bb0070 article-title: Early 18F-FDG PET for prediction of prognosis in patients with diffuse large B-cell lymphoma: SUV-based assessment versus visual analysis publication-title: J Nucl Med doi: 10.2967/jnumed.107.042093 contributor: fullname: Lin – start-page: 106 year: 2005 ident: 10.1093/annonc/mdn671_bb0085 article-title: Rituximab vs observation after high-dose consolidative first-line chemotherapy (HDC) with autoogous stem cell transplantation in poor risk diffuse large B-cell lymphoma. Final Analysis of the LNH98-B3 Study publication-title: Blood contributor: fullname: Haioun – volume: 23 start-page: 4652 year: 2005 ident: 10.1093/annonc/mdn671_bb0035 article-title: Response assessment of aggressive non-Hodgkin's lymphoma by integrated International Workshop Criteria and fluorine-18-fluorodeoxyglucose positron emission tomography publication-title: J Clin Oncol doi: 10.1200/JCO.2005.01.891 contributor: fullname: Juweid – volume: 23 start-page: 4117 year: 2005 ident: 10.1093/annonc/mdn671_bb0080 article-title: Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte publication-title: J Clin Oncol doi: 10.1200/JCO.2005.09.131 contributor: fullname: Feugier – volume: 48 start-page: 1522 year: 2007 ident: 10.1093/annonc/mdn671_bb0040 article-title: Aggressive and indolent non-Hodgkin's lymphoma: response assessment by integrated international workshop criteria publication-title: Leuk Lymphoma doi: 10.1080/10428190701474365 contributor: fullname: Brepoels – volume: 352 start-page: 1197 year: 2005 ident: 10.1093/annonc/mdn671_bb0075 article-title: ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma publication-title: N Engl J Med doi: 10.1056/NEJMoa042040 contributor: fullname: Reyes – volume: 25 start-page: 579 year: 2007 ident: 10.1093/annonc/mdn671_bb0045 article-title: Revised response criteria for malignant lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.09.2403 contributor: fullname: Cheson – volume: 13 start-page: 1356 year: 2002 ident: 10.1093/annonc/mdn671_bb0055 article-title: Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma publication-title: Ann Oncol doi: 10.1093/annonc/mdf256 contributor: fullname: Spaepen – volume: 49 start-page: 13 year: 2008 ident: 10.1093/annonc/mdn671_bb0020 article-title: 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review publication-title: J Nucl Med doi: 10.2967/jnumed.107.039867 contributor: fullname: Terasawa – volume: 91 start-page: 522 year: 2006 ident: 10.1093/annonc/mdn671_bb0015 article-title: 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review publication-title: Haematologica contributor: fullname: Zijlstra – volume: 106 start-page: 1376 year: 2005 ident: 10.1093/annonc/mdn671_bb0060 article-title: [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome publication-title: Blood doi: 10.1182/blood-2005-01-0272 contributor: fullname: Haioun – volume: 92 start-page: 778 year: 2007 ident: 10.1093/annonc/mdn671_bb0100 article-title: Respective prognostic values of germinal center phenotype and early (18)fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma publication-title: Haematologica doi: 10.3324/haematol.10895 contributor: fullname: Dupuis – year: 2001 ident: 10.1093/annonc/mdn671_bb0095 contributor: fullname: Jaffe – volume: 53 start-page: 457 year: 1958 ident: 10.1093/annonc/mdn671_bb0090 article-title: Non parametric estimation from incomplete observations publication-title: J Am Stat Assoc doi: 10.1080/01621459.1958.10501452 contributor: fullname: Kaplan – volume: 17 start-page: 1244 year: 1999 ident: 10.1093/annonc/mdn671_bb0030 article-title: Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group publication-title: J Clin Oncol doi: 10.1200/JCO.1999.17.4.1244 contributor: fullname: Cheson – volume: 104 start-page: 1066 year: 2005 ident: 10.1093/annonc/mdn671_bb0010 article-title: A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma publication-title: Cancer doi: 10.1002/cncr.21253 contributor: fullname: Isasi – volume: 26 start-page: 90 year: 2008 ident: 10.1093/annonc/mdn671_bb0105 article-title: Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2007.11.9248 contributor: fullname: Krishnan – volume: 16 start-page: 1514 year: 2005 ident: 10.1093/annonc/mdn671_bb0065 article-title: FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma publication-title: Ann Oncol doi: 10.1093/annonc/mdi272 contributor: fullname: Mikhaeel – volume: 25 start-page: 571 year: 2007 ident: 10.1093/annonc/mdn671_bb0050 article-title: Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma publication-title: J Clin Oncol doi: 10.1200/JCO.2006.08.2305 contributor: fullname: Juweid |
SSID | ssj0006929 |
Score | 1.9440908 |
Snippet | Background: Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of... Revised response criteria for aggressive lymphomas have been proposed (Cheson, J Clin Oncol, 2007) stressing the role of (18)fluorodeoxyglucose-positron... |
SourceID | proquest crossref pubmed pascalfrancis oup istex |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 503 |
SubjectTerms | 18fluorodeoxyglucose PET scan Adult Aged Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal - therapeutic use Antibodies, Monoclonal, Murine-Derived Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cyclophosphamide - administration & dosage Cyclophosphamide - therapeutic use diffuse large B-cell lymphoma Disease-Free Survival Doxorubicin - administration & dosage Doxorubicin - therapeutic use Female Fluorodeoxyglucose F18 Hematologic and hematopoietic diseases Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Large B-Cell, Diffuse - diagnostic imaging Lymphoma, Large B-Cell, Diffuse - drug therapy Male Medical sciences Middle Aged Pharmacology. Drug treatments Positron-Emission Tomography Prednisone - administration & dosage Prednisone - therapeutic use Prospective Studies response Criteria Rituximab Treatment Outcome Vincristine - administration & dosage Vincristine - therapeutic use |
Title | Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria |
URI | https://api.istex.fr/ark:/67375/HXZ-62XCSL54-K/fulltext.pdf https://www.ncbi.nlm.nih.gov/pubmed/19074215 https://www.proquest.com/docview/196630430/abstract/ |
Volume | 20 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Zb9NAEF71kBASQpwlFKpBQrxETuPb5q2krUJLAZVWinix1heNmktJLKX8bf4AM97DNrRQyINtrR17k5lvdvbz7Axjr20_zZ04MA0bTR-VMKP3u37XiDlZx8zsdlPiO04-ev1z52jgDtbWd2tRS8Uy7iTfr11X8j9SxTaUK62S_QfJ6ptiAx6jfHGLEsbtrWR8KgJcszbX-TVl0W9OAYyUypUCg3r9T58p7pz2xmh4SZVSvlFWf8HC4hnaU4DyfLgsVsMxj4kGMbu2Srsq18BRNZUCHzei8PH2O4NY__boChViOi5r_KjkE8Q_mEE-KqZon7Pp6kpFxpcxYnPUOCozR0Qd-r5jmTVbucFNkpLY_MXFdEYFyJYyKFq701X65-kkabwg2C9mhUifcNTR6r8UsQsHuuWUX4zR3JWte7q1T4umS-U77DRYkbAKC_vTass6_WnZBk7VBJmRSePvhQblY6qPDla3hgK7Zurdrl3zGlxRu_e3AUkk6-KTCf4NeDBOJ54oOdNM_f3LkKwDJfn8kiLvfDfqD75GnjXoffngOtHxOtu0_NAltmH__bF2PbzQEskl5Y-TSWWxE7uiC7uiAw0nbJPsyUot8Lw34wu0Drko63LzvKv0v84esPty4gR7AgUP2Vo2ecTunMjQkMfshwIDVGCAEgzAJ6DBAAQCmM5BgwEkGIBUnM5IMIAGA34bEAygwCCulGCAEgwgwAAKDG-hBgW4DgqgoAAKClBBAQ8BoQANKICCAigoPGHnhwdnvb4hK5oYCbqKpsE5OvDcTjM_DUIzw9lYShwCN0Mn8QIr4V6Yen7ueIGZO_ixQqrPkBCL4Xg41NpP2QaKMXvGIEcv0w_9OAkc23GtPMRZcpK6xAj4se9nLfZGiTiaicQ1kQg4sSOhC5HQBbywVAB91U0612KvUEP-drOdhv7oq8lDJu-sxbaVQkXSki4i9AI8m5IPttiW0LHqKSV5Z7rPb9vLbXa3sgcv2MZyXmQvcd6wjHdKrPwEDqgkgA |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Response+assessment+after+an+inductive+CHOP+or+CHOP-like+regimen+with+or+without+rituximab+in+103+patients+with+diffuse+large+B-cell+lymphoma%3A+integrating+18fluorodeoxyglucose+positron+emission+tomography+to+the+International+Workshop+Criteria&rft.jtitle=Annals+of+oncology&rft.au=Dupuis%2C+J.&rft.au=Itti%2C+E.&rft.au=Rahmouni%2C+A.&rft.au=Hemery%2C+F.&rft.date=2009-03-01&rft.pub=Oxford+University+Press&rft.issn=0923-7534&rft.eissn=1569-8041&rft.volume=20&rft.issue=3&rft.spage=503&rft.epage=507&rft_id=info:doi/10.1093%2Fannonc%2Fmdn671&rft.externalDBID=n%2Fa&rft.externalDocID=ark_67375_HXZ_62XCSL54_K |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0923-7534&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0923-7534&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0923-7534&client=summon |